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ABSTRACT
The nuclear receptors LXRa (NR1H3) and LXRb
(NR1H2) are attractive drug targets for the treatment
of diabetes and cardiovascular disease due to their
established role as regulators of cholesterol and
lipid metabolism. A large body of literature has
recently indicated their important roles in glucose
metabolism and particularly LXRb is important for
proper insulin production in pancreas. In this study,
we report that glucose induces transcription via the
LXRB gene promoter. The transcription start site of
the human LXRB gene was determined and we
identified two highly conserved, and functional, ETS
and Elk1 binding sites, respectively, in the LXRB
gene promoter. The Elk1 binding site also bound the
serum responsive factor (SRF). Mutation of these
sites abolished binding. Furthermore, mutation of
the binding sites or siRNA knockdown of SRF and
Elk1 significantly reduced the promoter activity and
impaired the glucose response. Our results indicate
that the human LXRB gene is controlled by glucose,
thereby providing a novel mechanism by which
glucose regulates cellular functions via LXRb.
INTRODUCTION
The occurrence of hyperlipidemia, hyperglycemia, insulin
resistance and its metabolic complications such as type-2
diabetes mellitus (T2DM) increases dramatically in the
western world. A deeper understanding of the pathogen-
esis causing these diseases and development of drugs
targeting metabolic disorders currently has high priority.
Nuclear receptors (NRs), including liver X receptors
(LXRs), have been suggested as potential drug targets
for the treatment or prevention of T2DM (1). LXRa and
LXRb are established regulators of cholesterol and lipid
metabolism and activation of LXRs promotes conversion
of cholesterol to bile acids, lipid/triglyceride biosynthesis
and reverse cholesterol transport from peripheral cells to
the liver and subsequent elimination of cholesterol via the
gall bladder [reviewed in (2)].
A large body of literature establishes an important
physiological role of LXR in carbohydrate metabolism.
The carbohydrate-response element-binding protein
(ChREBP) mediates glucose activated lipogenesis via the
xylulose 5-phosphate pathway (3) and has been identiﬁed
as an LXR target gene (4). Recently, glucose itself was
shown to be an LXR agonist activating LXRs at
physiological concentrations (5). Activation of LXR
promoted glucose uptake and glucose oxidation in
muscle (6). As skeletal muscle constitutes 40% of the
human body weight and is the major site for glucose
utilization, this observation suggests that LXR might have
a considerable impact on overall glucose oxidation in the
body. Expression of the insulin responsive glucose
transporter GLUT4 in adipocytes was induced by LXR
while the basal expression of GLUT4 was lower in
LXRa
 /  mice compared to wild type mice (7,8).
Increased glucose uptake in adipocytes and muscle cells
as well as reduced hepatic gluconeogenesis due to
suppressed expression of gluconeogenic genes including
PEPCK, G6P and PGC1a were observed in response to
treatment with an LXR agonist (6,8,9). Moreover, activa-
tion of LXR increased glucose dependent insulin secretion
in vitro from pancreatic b-cell line cultures (10) and lead
to increased plasma insulin concentrations in mice (11).
It was also shown that LXRb
 /  mice have less basal
insulin levels and, on a normal diet, are glucose intolerant
due to impaired glucose-induced insulin secretion (12).
LXR signaling seems more prominent in disease where,
for instance, impaired lipid oxidation was seen in isolated
muscle cells from T2DM patients compared to control cells
when the muscle cells were treated with an LXR agonist (6).
Further, improved glucose tolerance was observed in obese
C57Bl/6 mice in response to treatment with an LXR
agonist, but not in lean C57Bl/6 mice (8) and similar results
were observed in db/db mice, Zucker diabetic and obese
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insulin sensitivity was observed in ob/ob mice upon
activation of LXRs, but not in lean mice (13). Together,
these observations suggest an anti-diabetic role of LXRs.
Elk1 is a well-studied member of the ETS family of
transcription factors. Elk1 activity is tightly regulated by
phosphorylation and dephosphorylation which have been
extensively studied in the context of cellular signaling.
Elk1 has been shown to be positively regulated by
activation of the MAPK pathway including Erk1/2, p38
and JNK, which has been shown to be dysfunctional
in T2DM (15,16). Here we identify a 50-ETS site and a
30-Elk1 binding site in the human LXRB gene promoter
and show that Elk1 can bind both sites while SRF only
binds to the 30-Elk1 site. We show that binding of SRF
and Elk1 to the identiﬁed binding sites is important for
LXRB transcription. Furthermore, we report that glucose
signiﬁcantly induces transcription via the LXRB gene
promoter and that the identiﬁed binding sites are
important for proper glucose responsiveness.
MATERIALS AND METHODS
Rapid amplification of cDNA ends(RACE)
The LXRB gene speciﬁc primers 50-CGGCCTCTCGCGG
AGTGAACTACTCCTGTT-30 and nested 50-AGGCTG
AGCTGGCCTCATCAGTGCCTGGGA -30 were used
to amplify 50-transcript from full-length cDNA from
human testis, ovary and thymus using Marathon ready
cDNA kits (Clontech, Mountain View, CA, USA) with
the Expand Long Template PCR System (Boehringer
Mannheim, Mannheim, Germany) according to the
manufacturer’s instructions. The PCR products were
cloned into the pGEM-T easy vector (Invitrogen,
Carlsbad, CA, USA), and the identity of cloned products
determined by DNA sequencing.
Plasmid constructs
The pcDNA-Elk1 plasmid was generously provided by
Dr Robert Hipskind (Institut deGe ´ ne ´ tique Mole ´ culaire de
Montpellier, FRANCE). The SRF plasmids were a gift
from Dr Eric Olson (UT Southwestern Medical Center at
Dallas, USA). PCR fragments of the human LXRB gene
promoter were cloned into the pGL3-Basic luciferase
reporter vector (Promega, Madison, WI, USA)
using the KpnI and MluI sites with forward primers
( 3839) 50-ATCAGGTACCCTTTTACCTCATTTAGT
CATAAGAGTAAGGCAACAAGGTCA-30,(  1673)
50ATCAGGTACCAAAACAGCATATGCAGTAAAGAAGTCAGC
CAGATCCCAGCA-30 and ( 245) 50-ATCAGGTACCG
GCCGCAGGCTCAGAGAAGCGCATGAATGAGCT
AA-30 and reverse (+1163) 50-ATCACTCGAGGGTGG
GGTCACGGAGCAGCCTGTAGAATACAGGGGAT
TGAGAG-30 with the restriction enzyme sites underlined.
All mutations were introduced using the QuickChange
TM
XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA, USA). The -245/+1163 construct was further
mutated to destroy the putative Ets binding site using
primers 50- GATCTACCCGGTAAACTTTTGGTGAGT
TTCCAACTTCCG-30 and the corresponding reverse
compliment. The Elk1 binding site was mutated using
50-GGCAGCAGCTTCGGCTGGTCCTAAGCGGTTTT
TTTGTTCGTCAAGTTTCACGCTCCGCCCCTCTTCC
GG-30 and the reverse compliment primers. DNA
sequencing conﬁrmed the identity of all clones.
Transient transfections
The mouse MIN6 insulinoma cell line was maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, 4.5g/l
glucose), (GIBCO-BRL cat no. 41965-039), and the rat
INS1E insulinoma cell line was maintained in RPMI 1640,
including L-glutamine and 11.1mM glucose, (GIBCO-
BRL, cat no. 21875-034). Media were supplemented with
fetal bovine serum (INS1E: 10%, MIN6: 15%), 50mM
b-mercaptoethanol and penicillin/streptomycin at a ﬁnal
concentration of 100U/ml and 100mg/ml, respectively.
MIN6 medium also contained 2mM L-glutamine while
10mM HEPES and 1mM Sodium Puryvate were added to
INS1E medium. For serum and glucose starvation, INS1E
cells were grown in plain RPMI 1640 (11879-020) contain-
ing no serum or glucose. Cells were grown under 5% CO2
at 378C. Total 4 10
4 MIN6 and 25 10
4 INS1E cells
were seeded in 24-well plates and transiently transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. Each
well received 125ng of reporter vector and 500ng of
expression vector. Empty vehicle vector was added to
ensure equal amounts of DNA in each transfection. Cells
were transfected for 24h and thereafter lysed in 25mM
TAE, 1mM EDTA, 10% glycerol, 1% Triton X-100 and
2mM DTT. Luciferase activities were measured using a
Luciferase Assay Kit (BioThema, Umea ˚ , Sweden) in a
luminometer (Luminoscan Ascent, Thermo electron
Corporation, Waltham, MA, USA).
Whole cell extracts (WCE) and invitro translation/
transcription
Cells were grown in 24-well plates, washed with PBS and
incubated in TEN buﬀer (40mM Tris-HCl, 1mM EDTA,
150mM NaCl) for 4min. Cells were mechanistically
removed with a cell scraper and pelleted by centrifugation
at 3500 r.p.m. for 2min at 48C. Cell pellets were freeze
dried on dry ice and resuspended in 50ml ice-cold buﬀer C
(10mM HEPES-KOH pH 7.9, 0.4M NaCl, 0.1mM
EDTA, 5% glycerol, 1mM DTT, 0.5mM PMSF). After
another round of freeze drying, cell debris was removed by
centrifugation for 5min at 13000 r.p.m. at 48C. The
supernatant corresponds to whole cell extracts.
Electromobility shift assay(EMSA)
WT and mutated (‘Mut’) oligos (mutated nucleotides
underlined) were; ETS1:50-GATCTACCCGGTAAACT
TCCGGTGAGTTT-30, Elk1:50-GGTCCTAAGCGGAC
CGGAAGTTCGTCAAGTTTCA -30, Mut ETS1:50-G A
TCTACCCGGTAAACTTTTGGTGAGTTT -30 and
Mut Elk1:50-GGTCCTAAGCGGTTTTTTTGTTCGTC
AAGTTTCA-30. Five microgram of the respective for-
ward and reverse oligos were annealed in 20mM Tris-HCl
pH 7.8, 2mM MgCl2, 50mM NaCl by heating to 958C for
5min and slow cooling by 1.58C/min for 47 cycles.
Oligonucleotide probes were labeled by mixing 0.2mg
Nucleic Acids Research, 2007, Vol. 35, No. 14 4859annealed oligo with 250 mM non-radioactive dATP,
dGTP, dTTP, respectively, 1  Klenow buﬀer, 20mCi
32P
labeled dCTP (GE Lifesciences, Piscataway, NJ, USA)
and 1 Unit Klenow polymerase. Samples were incubated
for 20min at room temperature (RT) and the reactions
terminated by adding 0.5M EDTA. Probes were puriﬁed
using G-25 Nick Columns (GE Lifesciences) and the
eﬃciency of labeling determined using the 1214 Rackbeta
liquid scintillation counter (LKB Wallac, Markham,
Ontario, Canada). For binding reactions, 2mg of whole
cell extracts were incubated with 4 10
4c.p.m. of radio-
labeled oligonucleotide in binding buﬀer pH 8.0 (10mM
Tris-HCl, 1mM DTT, 1mM EDTA, 50mM KCl, 0.3%
BSA, 5% glycerol) including 1mg poly(dI/dC) and
1  Proteinase Inhibitor Cocktail (PIC). One microgram
DNA template was in vitro translated in a 50ml reaction
using the TNT Coupled Reticulocyte Lysate Systems
(Promega). From this, 5ml was used in EMSA binding
reactions. Binding reactions were incubated for 20min
at RT and protein–DNA interactions separated by
electrophoresis at 240V for 4h at 48C using 8%
polyacrylamide gels. The gels were dried and analyzed
by autoradiography. In supershift assays, 1mg of the
respective antibodies were added prior to the addition of
WCE or IVT protein.
Chromatin immunoprecipitation (ChIP) assay
INS1E cells were transfected with the LXRB gene
promoter containing reporter vectors and expression
vectors for 24h and protein–DNA were crosslinked
using 1% formaldehyde for 20min at RT. Cells were
washed and harvested in cold 1  PBS and pelleted. The
pellet was resuspended and incubated in cold RIPA buﬀer
(50mM Tris pH 8.0, 1mM EDTA, 0.5mM EGTA pH
8.0, 1% Triton X100, 0.1% Na deoxycholate, 140mM
NaCl and 1 PIC for 10min). DNA was sheared by
sonication, centrifuged for 10min at 13000 r.p.m. at 48C
and the supernatant incubated with 20ml protein A/G
sepharose/agarose (50% slurry in RIPA buﬀer) on a
rotating wheel for 2h at 48C. Fifty microliter of the
supernatant was immunoprecipitated with 25mg salmon
sperm DNA, 100mg BSA and 10mg of Elk1 antibody in
RIPA buﬀer at 48C on a rotating wheel over night.
Twenty-ﬁve microliter protein A/G slurry was added and
incubated for an additional 1h. The samples were
centrifuged at 5000 r.p.m. for 2min, the precipitates
washed twice with 1ml TSE I (1% Triton X100, 2mM
EDTA, 20mM Tris pH 8, 150mM NaCl), once with LiCl
buﬀer (20mM Tris-HCl pH 8, 1mM EDTA, 250mM
LiCl, 1% NP40, 1% Na deoxycholate) and twice with TE
buﬀer pH 7.4 and the protein–DNA complexes were
eluted with 100ml freshly prepared 1% SDS/TE by
incubation for 30min on a rotating wheel at RT following
658C over night. For input control, 10% of saved samples
were treated similarly to the immunoprecipitated samples.
Supernatants were puriﬁed using QIAQUICK columns
(QIAGEN, Hilden, Gemany). Five microliter of the elution
was used in each real-time qPCR reaction using
primers covering conserved sites in the rat promoter
(Forward:50-AGGCATCTCATTCGGTGGC-30 and
Reverse:50-GGAAAGGTGACAGACTTCCGG) or the
human promoter (Forward:50-CCGGAAGTTCG
TCAAGTTTCA and Reverse:50-TTGCGTCACGTCC
GGAA).
Quantitative PCR (qPCR)
Total RNA was prepared from cells using the RNeasy
mini kit (QIAGEN) according to the manufacturer’s
instructions. Here, 0.5mg total RNA was reverse tran-
scribed into cDNA using SuperscriptII and random
hexamer primers (Invitrogen). The concentration and
quality of the puriﬁed total RNA were determined
spectrophotometrically at OD260nm and by the
OD260/280 ratio, respectively. mRNA expression levels
were quantiﬁed using the ABI 7500 instrument and the
SYBR green technology (Applied Biosystems, Foster City,
CA, USA). All primers were designed with the Primer
Express Software version 2.0, a program speciﬁcally
provided for primer design using ABI qPCR instruments.
Hundred nanomolar of SYBR green assay primers were
used and for each primer pair a dissociation curve analysis
was carried out to ensure the speciﬁcity of the
qPCR ampliﬁcation. All primer pairs were designed over
exon–exon boundaries. All real time qPCR reactions were
performed in triplicates. We calculated relative changes
employing the comparative CT method using 18S as the
internal reference gene.
siRNA
INS1E cells were transfected for 4 days with mouse siElk1
and siSRF (both SMRT pool) oligos (Dharmacon,
Lafayette, CO, USA) using DharmaFECT
TM buﬀer
4 (Dharmacon) according to the manufacturer’s instruc-
tions. Importantly, R&D at Dharmacon conﬁrmed that
the oligo sequences used in the mouse SMRT pools for
Elk1 and SRF matched the rat sequence as well.
Non-targeting control (D-001210-01), siLuciferase and
siGAPDH were used as controls at corresponding
concentrations. After incubation, cells were either used
for WCE extraction for western blot analysis or used
for RNA preparation and subsequent real-time qPCR
analysis of knockdown.
RESULTS
Identification oftranscription start sitesin thehuman LXRB
gene promoter
Rapid ampliﬁcation of 50-cDNA ends (50-RACE) was
performed using diﬀerent tissue libraries to identify
transcription start sites and, consequently, the proximal
promoter region of the human LXRB gene promoter. No
exact transcriptional start site was observed, rather
transcription was initiated within a conﬁned region of
the promoter, in keeping with observations from other
TATA-less promoters and previous observations for the
mouse Lxrb gene promoter (17). We designated the most
50-transcription start site observed as +1 (Figure 1).
The human LXRB gene promoter containsconserved and
functional Elk1 andETS binding sites
The genomic sequences from mouse, rat, dog and cow
were aligned with the corresponding identiﬁed proximal
4860 Nucleic Acids Research, 2007, Vol. 35, No. 14promoter region of human LXRB. Using a theoretical
transcription factor binding site search [Transcription
Element Search System (TESS); http://www.cbil.upenn.
edu/cgi-bin/tess/tess] two highly conserved binding sites
were identiﬁed, Elk1 and ETS (Figure 2A). The ETS site
is located 50 of the Elk1 site in the LXRB gene
promoter (Figure 2B). Next, we used EMSA to analyze
protein–DNA interactions at the identiﬁed binding sites
  * * * *     2*   2**   *     * 
+1       ¤     2¤ 
TTTCACGCTCCGCCCCTCTTCCGGACGTGACGCAAGGGCGGGGTTGCCGGAAGAAGTGGCGAAGTTACTTTTGAG
       *       **  2**  *  *  *  2*    *  * 
¤ ¤¤2¤      2¤        ¤2¤   ¤  2¤         ¤  ¤  ¤¤2¤ 
¤ 
      4#       8# 
GGTATTTGAGTAGCGGCGGTGTGTCAGGGGCTAAAGAGGAGGACGAAGAAAAGCAGAGCAAGGGAACCCAGGTAG 
GTGCACCCGAGAGTGGGGAGACGCAGTAGGTGCACCCGAGAGTGGGGAGACGCAGGAGGAGCCCCGAACCCGGGG 
CTTCTCGGCGCTCCCCGCGTACTCCGCTCTGCCCCCTTCTCTCCTTCCATTTCCTCCCCTCGGTAATTCGCGCCT 
CCCGCGGCTGTTTCCAGGGCAACAGGAGTAGTTCACTCCGCGAGAGGCCGTCCACGAGACCCCCGCGCGCAGCCA
+390 
TGAGCCCCGCCCCCCGCTGTTGCTTGGAGAGGGGCGGGACCTGGAGAGAGGTGCGA 
Figure 1. Characterization of the transcriptional start site of the human LXRB gene using 50 RACE. 50 RACE was performed using ovary (
 ),
testis (¤) and thymus (#) cDNA libraries as described in Materials and Methods Section. Numbers indicate how many transcripts (if more than one)
with a speciﬁc start site that were identiﬁed by sequencing of RACE products. Published exon sequences found in the NCBI database are underlined.
The translational start site (ATG) is at +1339 but not shown in this ﬁgure.
A
dog    GCCCCCTCCC GCACTACATT CGGTGGAACT GGTCCGGAAC TCTCCTGCCA GGCCTCGGTG 
human  .....CTCCC A....AGAAG CGAGGAAATG GGTTCGGAAC TCTTCTGCCA AGTCCCAGTA 
rat    .TCATGTGTT TAA..AGAAA CAAAAGAACT T.TCCGGAAC TTTTTT.CTG AGTCCCAGAG 
mouse  .CCACCTGCG AAA..AGAAA CGAAAGAACT T.TCCGGAAC TTTTTT.CTG AGTCCCAGAG 
cow    .CGCCCTACT GCCCAACATT TGACTGAATG GGTCAGGAAC TCTTCCGCCC GCCCTCATCC 
dog    G..AAATACT CCGGACGGTA AGCTTCCGGT GAGAATACGA CTTCCGTGCG GGGCAGCCGA 
human  G..ATCTACC C.....GGTA AACTTCCGGT GAGTTTCCAA CTTCCGTGCG GGGCAGCAGC 
rat    GGGAACTACC AGAAGAAATA AACTTCCGGT G....TCCCA CTTCCGGCCA AGGCATCTCA 
mouse  GGGAACTACC AGAAGAAATA AACTTCCGGT G....TGCCA CTTCCGGCCG AGGCCTCACA 
cow    T..AGTTACC CGGAAACGCA AACTTCCGGT GGGTCCACGA CTCCGACGCG GGGCAGCCCA 
-117 <--cETS--- -108
dog    TTTGGCTAGT ..TAAGCGGA CCGGAAGTCC GTCACTCCTG ACTGCCCGCC CC.CTTCCTA 
human  TTCGGCTGGT CCTAAGCGGA CCGGAAGTTC GTCAAGTTTC ACGCTCCGCC CCTCTTCCGG 
rat    TTCGGTGGCG CCTAGGCAGA CCGGAAGTCT GTCACCTTTC CCGGCCCTCC TA.CTTCCGG 
mouse  GTCGGTGGCG CCCTGGCAGA CCGGAAGTCT GTCACCTTTC CCGGTCCGCC TA.CTTCCGG 
cow    TTACGCTATC CCTGGACGAA CCGGAATTTC GTCACCCC.G ACTACCCGCC CA.CTCCCGG 
-61 -------Elk1------> -46
dog    AAGTGACGCA CGG.CGGGGT TGCCGGAAGA AGTGGCGAAG TTACTTTTGA GGGGATCCGA 
human  ACGTGACGCA AGGGCGGGGT TGCCGGAAGA AGTGGCGAAG TTACTTTTGA GGGTATTTGA 
rat    AAGTGACGCG CAG.CGGGGT TGCCGGAAGA AGTGGCGAAG TTACTTTTGC TTTTCGCTCA 
mouse  AAGTGACGCG CAG.CGGGGT TGCCGGAAGA AGTGGCGAAG TTACTTTTGC TTTTCGCTCA 
cow    AAGTGACGCA CGG.TGGGGT TGCCGGAAGA AGTGGCGAAG TTACTTTTGA .......... 
dog    GAAGCGGCGG CGTGCCAGGG GATACAGAGA AGGAGGAGGA AAAGCAGAGC AAGGGGACAG 
human  GTAGCGGCGG TGTGTCAGGG GCTAAAGAGG AGGACGAAGA AAAGCAGAGC AAGGGAACCC 
rat    GCAAGCGCTG T.TGCTCCGA GCTACTCCCA GG..CTTCTG AAGTTACTTC TGA....... 
mouse  GCAAGCGCTG T.TGCTTCGA GCTACTCCCA GG..CTTCTG AAGTTACTTC CAAAGTGCTG 
cow    .......... .......... .......... .......... .......... .......... 
ETS Elk1
−117  −108 −61  −46 
Exon1 
+1
Intron1 
EMSA oligos
ETS Elk1
B
Figure 2. Two conserved Elk1 and ETS sites are found in the LXRB gene promoter. (A) The LXRB promoter sequences from human, dog, rat,
mouse and cow are aligned. Highly conserved Elk1 and an ETS transcription factor binding sites were identiﬁed. The binding sites are shown in bold
where the ETS and Elk1 sites are in the 30-50 and 50-30 orientation, respectively as indicated by the arrows. The transcriptional start site at G (+1) is
marked in red. (B) The identiﬁed 50-ETS site and 30-Elk1 site in the human LXRB gene promoter are schematically depicted. The location of the
DNA oligos used in EMSA experiments is indicated.
Nucleic Acids Research, 2007, Vol. 35, No. 14 4861using independent DNA oligos covering these sites
depicted in Figure 2B. Bands representing protein–DNA
interactions at both the wild type Elk1 and ETS binding
sites were observed using whole cell extract (WCE)
and in vitro translated (IVT) Elk1 protein (Figure 3A,
lanes 1–5 and 3C, lanes 1–3) and the interactions were
abolished when these binding sites were mutated
(Figure 3A, lanes 6–10 and 3C, lanes 4–6). The IVT
Elk1 interactions were supershifted using a speciﬁc
Elk1 antibody or an HA antibody (Elk1 cDNA was
HA-tagged), but no supershift was observed using an
antibody directed against the transcription factor C/EBPb
indicating a speciﬁc binding of Elk1 to this site (Figure 3B,
lanes 1–6).
WCE yielded a complex which migrated more slowly
compared to the pure IVT Elk1 protein indicating
that additional proteins forming larger complexes were
responsible for the interaction observed using WCE.
Figure 4A, lanes 1–4 show that IVT Elk1 and SRF bind
to the wild type Elk1 binding site, although the Elk1
interaction seems to be stronger. Both proteins were
equally expressed in our in vitro transcription/translation
system (Figure 4C) suggesting that this is not due to a
molar diﬀerence for the two proteins, rather, this might
simply be due to the composition of the EMSA binding
buﬀer used, favoring Elk1 binding. Both SRF and Elk1
binding was abolished when the Elk1 binding site was
mutated (lanes 5–6). Combining both IVT Elk1 and SRF
yielded two bands of smaller size than observed using
WCE but of the same size as when IVT Elk1 and SRF
were used separately (Figure 4B, lanes 1–4) suggesting that
in vitro translated Elk1 and SRF do not by themselves
form the same complex as seen in WCE. SRF did not
interact with the ETS binding site (data not shown).
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Figure 3. There are functional Elk1 and ETS binding sites in the LXRB gene promoter. (A) An oligo covering the wild type LXRB gene promoter
Elk1 binding site (WT Elk1-oligo) and a mutated Elk1 site (Mut Elk1-oligo) were incubated with whole cell extracts (WCE) from the rat insulinoma
INS1 cell line (lanes 2 and 7) or in vitro translated (IVT) Elk1 (lanes 4, 5, 9 and 10) or the empty control plasmid (lanes 3 and 8). IVT Elk1 Mut
has three mutated regulatory phosphorylation sites. (B) WT Elk1-oligo was incubated with empty control plasmid (lane 2) or IVT Elk1 protein
(lanes 3–6) in the presence of antibodies directed against the transcription factor C/EBPb (lane 4), the HA-tag (lane 5) or Elk1 (lane 6). (C) An oligo
covering the wild type LXRB gene promoter ETS binding site (WT ETS-oligo) and a mutated ETS site (Mut ETS-oligo) was incubated with whole
cell extracts (WCE) from the rat insulinoma INS1 cell (lanes 1 and 4) or IVT ETS (lanes 3 and 6) or the empty control plasmid (lanes 2 and 5).
4862 Nucleic Acids Research, 2007, Vol. 35, No. 14Furthermore, we performed ChIP assays in the INS1 cell
line to analyze the interaction of Elk1 and SRF on the
transfected human LXRB proximal promoter and
the native rat promoter in the INS1 cell line using a
non-speciﬁc IgG antibody as control. The LXRB gene
promoter was transiently transfected into INS1 cells
before crosslinking of DNA and proteins. Elk1 was
enriched at the identiﬁed binding sites and the enrichment
was strongly increased upon overexpression of Elk1 before
crosslinking (Figure 5A). Similar results were seen on the
endogenous rat Lxrb gene promoter where endogenous
Elk1 was found to be enriched (Figure 5C and scaled up in
the inserted frame) and this enrichment was strongly
enhanced upon overexpression of Elk1. No enrichment of
Elk1 was seen when the LXRB gene promoter with
mutated binding sites for Elk1 and ETS was transiently
transfected (Figure 5B). This indicates that Elk1 is
associated with its binding site at the endogenous
promoter. No enrichment was seen using primers amplify-
ing the luciferase gene (used as control for the over-
expressed reporter gene experiment) or primers amplifying
an exon in the Lxrb gene (used as control for the rat native
Lxrb promoter experiments) (data not shown) indicating
that the enrichment is speciﬁc for the identiﬁed binding sites
SRE. Unfortunately, we could not get any of the antibodies
directed against SRF to work in the ChIP assay.
Next we investigated the eﬀect of knocking down
Elk1 and SRF in the INS1 cell line. A signiﬁcant knock-
down of either Elk1 or SRF was observed with siRNA
targeting Elk1 or SRF but not with unrelated siRNA used
as controls. The eﬃcacy of siRNA knockdown was
anlyzed at the RNA level using qPCR for Elk1
(Figure 6A) and at the protein level using western analysis
for SRF (Figure 6B); in the latter case b-actin was used as
a control. No cytotoxicity was observed even at 500nM
siRNA (data not shown). Using WCE from the INS1 cell
line after transfection with siRNA targeting either Elk1 or
SRF almost completely abolished binding to the Elk1 site
in the LXRB gene promoter (Figure 6C, lanes 4, 5, 9 and
10) while control siRNAs did not aﬀect the protein–DNA
interaction at the Elk1 site (lanes 1, 2, 3, 6, 7 and 8). These
results suggest that both Elk1 and SRF must be present
for adequate transcription factor complex formation at
the binding sites in the LXRB gene promoter.
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In order to characterize the importance of the identiﬁed
transcription factor binding sites for transcription of the
LXRB gene we cloned the  245 to +1163 LXRB gene
regulatory region in front of the luciferase reporter gene.
We knocked down expression of Elk1 and SRF in the
INS1 cell line by siRNA targeting Elk1, SRF or both and
then transiently transfected the  245/+1163 LXRB gene
promoter construct. A signiﬁcant reduction in promoter
activity was observed when the levels of Elk1 and SRF
were reduced (Figure 7A). Second, the Elk1 site, the ETS
site or both sites (the same mutations were used here as the
ones which showed abolished binding in Figures 3 and 4)
were mutated in the  245/+1163 LXRB promoter
constructs and transiently transfected into the INS1 cell
line. The individually mutated Elk1 or ETS sites reduced
promoter activity by 50–60% while the activity was
reduced by 90% in the double mutation (Figure 7B),
suggesting that both binding sites are necessary for full
activity and that both Elk1 and SRF induce transcription
via these binding sites in the LXRB gene promoter.
Glucose inducestranscription via theLXRB gene promoter
A strong induction in expression of known LXR
target genes including the ATP-binding cassette (ABC)
transmembrane cholesterol and lipid transporters
(ABCA1 and ABCG1) and the lipogenic sterol regulatory
element-binding protein 1c (SREBP1c) transcription
factor was observed when INS1 cells were treated with
an LXR agonist (Figure 8A) indicating that LXR
signaling in these cells is working properly. Furthermore,
the INS1 cells showed the expected induction in expres-
sion of pyruvate kinase upon treatment with increasing
concentrations of glucose (18) (Figure 8B) while
the endogenous expression of LXRb was not aﬀected
by glucose treatment (Figure 8C). Neither was the
endogenous expression of LXRb using primary pancreatic
b-cells from rat aﬀected with glucose treatment (data not
shown). LXRB gene promoter constructs with wild
type or mutated Elk1, ETS or mutations of both sites
were transiently transfected into INS1 cells and the cells
were treated with increasing concentrations of glucose
(Figure 9). As expected and in keeping with Figure 7B,
the basal activities of the mutated constructs were
reduced. Surprisingly, a signiﬁcant concentration depen-
dent induction of the wild type promoter activity was
observed with glucose treatment whereas the double
mutated Elk1 and ETS construct showed reduced
response to glucose. This shows that glucose signiﬁcantly
induces transcription via the wild type LXRB gene
promoter. Furthermore, both the ETS site and the Elk1
site are involved in proper glucose response as the activity
of the double mutant construct at 20mM glucose only
showed an activity similar to that of the WT promoter
under starved conditions.
The eﬀect of glucose on the promoter was surprising
since endogenous expression of LXRb in the INS1 cell line
was not aﬀected by increasing concentrations of glucose
(Figure 8C). Therefore, we cloned larger 50-regions of the
human LXRB gene promoter as indicated in Figure 10 to
look for regions which might cause repression of
transcription. Transient transfections of equimolar
amounts of the promoter–reporter vectors showed
that inclusion of upstream regions signiﬁcantly reduced
the activity of the promoter. The  3839/+1163 construct
still mediated a glucose response, but this response
was markedly reduced compared to that seen with the
 245/+1163 construct (data not shown). We speculate
that these repressive elements and others located outside
the fragments we have cloned suppress endogenous
activation by glucose. Thus, additional cell signaling
pathways could be responsible for targeting these repres-
sive functions which apparently overrun the stimulating
eﬀects of glucose on the LXRB promoter.
DISCUSSION
Together with the SRF, the ETS family of transcription
factors is known to form a transcription complex which
can bind the serum response element (SRE). An SRE
normally consists of a 50-binding site which can recruit
members of Elk1 and ETS transcription factor family
and a 30-binding site which recruits SRF. SRF binds to
the 30-binding site and associates with a member of the
Elk1-ETS-family of transcription factors at the 50-binding
site and consequently the transcription complex occupies
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4866 Nucleic Acids Research, 2007, Vol. 35, No. 14both binding sites (15). The identiﬁed 30- binding site in
the LXRB gene promoter was not a consensus
SRF binding site as reported in the literature (16).
Thus, our identiﬁed binding sites do not represent a
classical SRE. Nevertheless, in this study we identify two
binding sites in the human LXRB gene promoter which
are highly conserved between species. Using mammalian
cellular systems our results indicate that the ETS site and
the Elk1 site are involved in increasing transcription via
the LXRB gene promoter. Interestingly, we also show that
the promoter is strongly responsive to glucose, partially
through mediation by these binding sites in the promoter.
Mutating both the Elk1 and ETS binding sites in the
LXRB, gene promoter strongly reduced its activity and
suppressed its response to glucose indicating that these
sites are important for both basal promoter activity and
promoter responses to glucose. However, the mutations
did not completely abolish the glucose response, indicat-
ing involvement of additional transcriptional regulatory
factors. Both the INS1 and MIN6 cell lines were analyzed
for changes in endogenous levels of LXRb after treatment
of glucose. Both overexpression of Elk1 and/or SRF as
well as siRNA targeting both factors was performed in
presence or absence of glucose. Surprisingly, none of these
treatments had any eﬀect on the endogenous expression of
LXRb. Neither did glucose treatment lead to any changes
in recruitment of Elk1 or SRF to the endogenous rat
LXRb promoter in the INS1 cells or the transfected
human LXRb promoter as analyzed by ChIP (data not
shown). Immortal cell lines do not always reﬂect responses
in normal cells from where the immortal cells originate.
Interestingly, however, neither was any eﬀect of glucose
treatment seen on LXRb expression in primary pancreatic
b-cells from rat (data not shown). Therefore, it cannot be
excluded that a glucose responsive human LXRB promo-
ter is conﬁned to human cells since these cells have
the necessary transcriptional network for the response
in question. Unfortunately, human primary pancreatic
b-cells are very diﬃcult to obtain so we could not test this
notion in a human primary cell system. However, the
identiﬁed binding sites are highly conserved between
species from mouse, rat, cow, dog and human (Figure 2)
and, therefore, we do not expect to see any species speciﬁc
eﬀect using primary islets from human. This is also
supported by our observation that Elk1 is enriched at the
endogenous Lxrb gene promoter in rat (Figure 5B).
Rather, we speculate that more complex cell signaling
mechanisms including additional transcription factors,
which modify the chromatin structure on the native
promoter, are necessary for endogenous glucose response.
The biological eﬀects of glucose, directly aﬀecting
transcriptional regulation of target genes (for instance
via ChREBP) or via insulin-mediated signaling, are
pivotal for overall energy homeostasis. Therefore, it is
conceivable that the glucose-activated transcriptional reg-
ulatory pathways are under strict and complex control.
Treatment of the MIN6 insulinoma cell line with
glucose activates Elk1 by phosphorylation of the Ser
368
residue which could lead to induced expression of Elk1
target genes (19). We show that Elk1 with the phosphor-
ylation sites Ser
324, Ser
383 and Ser
389 mutated to alanine
interacts with its binding site in the LXRB gene promoter
(Figure 3A), but has weaker eﬀects on transcriptional
regulation of the LXRB gene promoter (data not shown).
Thus, phosphorylation of Elk1 could alter the eﬀect of
Elk1 on transcription. Furthermore, insulin has been
shown to phosphorylate Elk1, thereby inducing its
transcriptional activity (20). Accordingly, several impor-
tant signaling events in response to metabolic processes
may inﬂuence Elk1 activity and potentially alter the
expression of LXRb. Thus, the regulation of Elk1 activity
is important for its eﬀect on the targeted promoter.
Multiple signaling cascades involved in cell growth and
proliferation including the mitogen-activated protein
kinases (MAPKs) have been identiﬁed as activators of
the SRF/TCF complex and factors that form these
complexes (15). These signals can work via SRF/TCF to
regulate gene expression. For instance, a dominant
negative Elk1 was shown to inhibit cell proliferation and
induce apoptotic cell death (21) and the TCF is a
docking site for the pro-proliferative Wnt signaling
cascade via b-catenin, which is known to interact with
several members of the NR family and regulate cell
proliferation events (22). LXRs were recently shown to
induce growth arrest and promote apoptosis in the INS1
insulinoma cell line (23) and several additional
studies report that LXRs mediate anti-proliferative eﬀects
(24–26). Hence, cell signaling cascades targeting TCF
might also elicit anti-proliferative eﬀects by enhancing
expression of LXRb.
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Figure 10. The 50-regions in the human LXRB gene promoter reduce its activity. INS1 and MIN6 cells were transfected with reporter vectors
representing three diﬀerent lengths of the LXRB gene promoter for 24h. The promoter activities were analyzed by a luciferase assay and the activity
of the various lengths of the promoter related to that containing the short fragment which was set to 100%  SEM.
Nucleic Acids Research, 2007, Vol. 35, No. 14 4867The role(s) of LXRs in various aspects of glucose
metabolism and as mediators of biological eﬀects of
glucose render LXRs highly interesting to study in the
attempts to deﬁne molecular mechanisms behind insulin
resistance and diabetes.
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